Precision Therapeutics (NASDAQ:POAI) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.
This is a breakdown of current ratings for Precision Therapeutics and Inogen, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Precision Therapeutics and Inogen’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precision Therapeutics||$1.41 million||11.00||-$10.09 million||N/A||N/A|
|Inogen||$358.11 million||3.03||$51.85 million||$2.30||21.53|
Inogen has higher revenue and earnings than Precision Therapeutics.
This table compares Precision Therapeutics and Inogen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
0.7% of Precision Therapeutics shares are owned by institutional investors. 16.5% of Precision Therapeutics shares are owned by insiders. Comparatively, 4.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Precision Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
Inogen beats Precision Therapeutics on 7 of the 11 factors compared between the two stocks.
Precision Therapeutics Company Profile
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.
Inogen Company Profile
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.